S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
Log in
NASDAQ:IMMP

Immutep News Headlines

$2.61
-0.10 (-3.69 %)
(As of 03/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.60
Now: $2.61
$2.74
50-Day Range
$2.68
MA: $3.16
$3.56
52-Week Range
$0.53
Now: $2.61
$7.95
Volume151,398 shs
Average Volume805,333 shs
Market Capitalization$127.27 million
P/E RatioN/A
Dividend YieldN/A
Beta2.23

Headlines

Immutep (NASDAQ IMMP) News Headlines Today

Source:
SourceHeadline
Immutep (NASDAQ:IMMP) Stock Passes Below 50 Day Moving Average of $3.16Immutep (NASDAQ:IMMP) Stock Passes Below 50 Day Moving Average of $3.16
americanbankingnews.com - March 4 at 2:22 AM
Immutep (NASDAQ:IMMP) Trading 5.2% Higher Immutep (NASDAQ:IMMP) Trading 5.2% Higher
americanbankingnews.com - February 24 at 10:38 PM
Immutep (NASDAQ:IMMP) Trading Down 7%Immutep (NASDAQ:IMMP) Trading Down 7%
americanbankingnews.com - February 22 at 9:20 PM
Immutep (NASDAQ:IMMP) Shares Cross Below 50 Day Moving Average of $3.25Immutep (NASDAQ:IMMP) Shares Cross Below 50 Day Moving Average of $3.25
americanbankingnews.com - February 19 at 4:20 AM
Short Interest in Immutep Limited (NASDAQ:IMMP) Declines By 72.6%Short Interest in Immutep Limited (NASDAQ:IMMP) Declines By 72.6%
americanbankingnews.com - February 11 at 3:16 PM
Immutep (NASDAQ:IMMP) Shares Up 9.2%Immutep (NASDAQ:IMMP) Shares Up 9.2%
americanbankingnews.com - February 9 at 7:40 PM
Immuteps lead candidate efti moves forward in mid-stage COVID-19 study - Seeking AlphaImmutep's lead candidate efti moves forward in mid-stage COVID-19 study - Seeking Alpha
seekingalpha.com - January 27 at 6:07 PM
Immutep Announces Advancement Of Phase II Trial For Eftilagimod Alpha In Covid-19 Patients To Randomised Portion Of The Study - GlobeNewswireImmutep Announces Advancement Of Phase II Trial For Eftilagimod Alpha In Covid-19 Patients To Randomised Portion Of The Study - GlobeNewswire
globenewswire.com - January 27 at 6:07 PM
Form 6-K IMMUTEP Ltd For: Jan 22 - StreetInsider.comForm 6-K IMMUTEP Ltd For: Jan 22 - StreetInsider.com
streetinsider.com - January 25 at 1:17 PM
Immutep Limited (IMMP) Announces Licensing Partner GSK to Discontinue Ulcerative Colitis Phase II Clinical Trial Evaluating GSK2831781 - StreetInsider.comImmutep Limited (IMMP) Announces Licensing Partner GSK to Discontinue Ulcerative Colitis Phase II Clinical Trial Evaluating GSK2831781 - StreetInsider.com
streetinsider.com - January 25 at 8:16 AM
With SPAC Deal Completed, Golden Nugget Online Gaming Stock Can Move Forward - NasdaqWith SPAC Deal Completed, Golden Nugget Online Gaming Stock Can Move Forward - Nasdaq
nasdaq.com - January 22 at 9:14 AM
Ulcerative Colitis Phase II Study of GSK2831781 Discontinued - GlobeNewswireUlcerative Colitis Phase II Study of GSK2831781 Discontinued - GlobeNewswire
globenewswire.com - January 22 at 9:14 AM
Toni Pearen recounts disturbing encounter with director as a young girl - Yahoo Finance AustraliaToni Pearen recounts disturbing encounter with director as a young girl - Yahoo Finance Australia
au.finance.yahoo.com - January 21 at 11:42 PM
Immutep Quarterly Activities Report Nasdaq:IMMP - GlobeNewswireImmutep Quarterly Activities Report Nasdaq:IMMP - GlobeNewswire
globenewswire.com - January 21 at 11:42 PM
Ulcerative Colitis Phase II Study of GSK2831781 DiscontinuedUlcerative Colitis Phase II Study of GSK2831781 Discontinued
finance.yahoo.com - January 21 at 6:41 PM
Immutep Quarterly Activities ReportImmutep Quarterly Activities Report
finance.yahoo.com - January 21 at 6:41 PM
Immutep Gets An Incomplete - Seeking AlphaImmutep Gets An Incomplete - Seeking Alpha
seekingalpha.com - January 19 at 6:01 PM
Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study - Yahoo FinanceImmutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study - Yahoo Finance
finance.yahoo.com - January 8 at 12:37 AM
Immutep Limited (IMMP) Reports Complete Recruitment of Head & Neck Cancer Patients of Phase II TACTI-002 Study - StreetInsider.comImmutep Limited (IMMP) Reports Complete Recruitment of Head & Neck Cancer Patients of Phase II TACTI-002 Study - StreetInsider.com
streetinsider.com - January 7 at 2:34 PM
Immutep completes recruitment in efti mid-stage study in head & neck cancer - Seeking AlphaImmutep completes recruitment in efti mid-stage study in head & neck cancer - Seeking Alpha
seekingalpha.com - January 7 at 2:34 PM
Immutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study - GlobeNewswireImmutep Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 Study - GlobeNewswire
globenewswire.com - January 6 at 11:32 PM
Immutep Limited (IMMP) Gains on US Patent Grant - StreetInsider.comImmutep Limited (IMMP) Gains on US Patent Grant - StreetInsider.com
streetinsider.com - January 1 at 10:14 PM
The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZenecas Vaccine Candidate, Hepion NASH Data - Yahoo FinanceThe Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data - Yahoo Finance
finance.yahoo.com - December 30 at 12:28 PM
Immutep Secures US Patent For Cancer Drug; Shares Jump 9.5% - NasdaqImmutep Secures US Patent For Cancer Drug; Shares Jump 9.5% - Nasdaq
nasdaq.com - December 30 at 7:27 AM
Why AVZ Minerals, Immutep, Kogan, & Strategic Elements shares are pushing higher - The Motley Fool AustraliaWhy AVZ Minerals, Immutep, Kogan, & Strategic Elements shares are pushing higher - The Motley Fool Australia
fool.com.au - December 30 at 1:08 AM
Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor - GlobeNewswireImmutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor - GlobeNewswire
globenewswire.com - December 29 at 7:53 PM
IMMP.O - Immutep Ltd Profile | ReutersIMMP.O - Immutep Ltd Profile | Reuters
reuters.com - December 23 at 10:49 PM
Immutep (ASX:IMM) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway - Yahoo FinanceImmutep (ASX:IMM) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway - Yahoo Finance
finance.yahoo.com - December 19 at 11:41 PM
Why the Immutep (ASX:IMM) share price is on watch today - The Motley Fool AustraliaWhy the Immutep (ASX:IMM) share price is on watch today - The Motley Fool Australia
fool.com.au - December 16 at 7:21 PM
Immutep Upscales Efti Manufacturing Nasdaq:IMMP - GlobeNewswireImmutep Upscales Efti Manufacturing Nasdaq:IMMP - GlobeNewswire
globenewswire.com - December 16 at 7:21 PM
Immutep Upscales Efti ManufacturingImmutep Upscales Efti Manufacturing
finance.yahoo.com - December 16 at 9:07 AM
Immutep Operational Update - Yahoo FinanceImmutep Operational Update - Yahoo Finance
finance.yahoo.com - December 15 at 2:10 PM
Immutep Operational UpdateImmutep Operational Update
finance.yahoo.com - December 15 at 9:06 AM
Arvinas News Alert: Why ARVN Stock Is Skyrocketing Today - InvestorPlaceArvinas News Alert: Why ARVN Stock Is Skyrocketing Today - InvestorPlace
investorplace.com - December 14 at 6:04 PM
Silver Spike, Immutep, 8x8: 5 Top Stock Gainers for Thursday - TheStreetSilver Spike, Immutep, 8x8: 5 Top Stock Gainers for Thursday - TheStreet
thestreet.com - December 10 at 4:13 PM
ASX stock of the day: Immutep (ASX:IMM) shares blast up 60% on trial news - The Motley Fool AustraliaASX stock of the day: Immutep (ASX:IMM) shares blast up 60% on trial news - The Motley Fool Australia
fool.com.au - December 10 at 4:13 PM
Why Greenwich LifeSciences, Immutep And Tenet Are Trading Higher Today - BenzingaWhy Greenwich LifeSciences, Immutep And Tenet Are Trading Higher Today - Benzinga
benzinga.com - December 10 at 4:13 PM
Immutep, Greenwich LifeSciences leads healthcare gainers; Xenetic Biosciences, Oncternal Therapeutics among major losers - Seeking AlphaImmutep, Greenwich LifeSciences leads healthcare gainers; Xenetic Biosciences, Oncternal Therapeutics among major losers - Seeking Alpha
seekingalpha.com - December 10 at 4:13 PM
Analyzing The Price Action In Immutep Stock Today - BenzingaAnalyzing The Price Action In Immutep Stock Today - Benzinga
benzinga.com - December 10 at 4:13 PM
Immuteps Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study - BenzingaImmutep's Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study - Benzinga
benzinga.com - December 9 at 6:10 PM
Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer - GlobeNewswireImmutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer - GlobeNewswire
globenewswire.com - December 9 at 6:10 PM
Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast CancerImmutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer
finance.yahoo.com - December 9 at 6:10 PM
Immutep’s Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer StudyImmutep’s Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study
finance.yahoo.com - December 9 at 6:10 PM
Immutep to enroll additional patients in mid-stage study with its lead cancer program - Seeking AlphaImmutep to enroll additional patients in mid-stage study with its lead cancer program - Seeking Alpha
seekingalpha.com - November 19 at 1:48 PM
Why a2 Milk, Crown, Immutep, & Suncorp shares are dropping lower - Motley Fool AustraliaWhy a2 Milk, Crown, Immutep, & Suncorp shares are dropping lower - Motley Fool Australia
fool.com.au - November 19 at 3:47 AM
Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development - GlobeNewswireImmutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development - GlobeNewswire
globenewswire.com - November 19 at 3:47 AM
Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development - Yahoo FinanceImmutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development - Yahoo Finance
finance.yahoo.com - November 18 at 10:32 PM
Immutep Announces Expansion of TACTI-002 Collaboration Trial - GlobeNewswireImmutep Announces Expansion of TACTI-002 Collaboration Trial - GlobeNewswire
globenewswire.com - November 18 at 10:32 PM
Immuteps Phase II TACTI-002 Study Reports Encouraging Data at SITC - GlobeNewswireImmutep's Phase II TACTI-002 Study Reports Encouraging Data at SITC - GlobeNewswire
globenewswire.com - November 10 at 2:02 AM
Immutep rallies on Australian patent grant for IMP701 antibodyImmutep rallies on Australian patent grant for IMP701 antibody
seekingalpha.com - November 9 at 9:01 PM
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.